<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Oral Antidiabetic Agents | Pharmacology</title>
    
    <!-- Preconnect for performance -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    
    <!-- Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- Main Stylesheet -->
    <link rel="stylesheet" href="../styles/main.css">
    
    <!-- MathJax Configuration -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <!-- Skip Link for Accessibility -->
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <!-- Reading Progress Bar -->
    <div class="reading-progress-container" aria-hidden="true">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Theme Toggle -->
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="page-wrapper">
        <!-- Floating Mini-TOC -->
        <aside class="floating-toc" id="floating-toc" aria-label="On this page">
            <div class="floating-toc-header">
                <span class="floating-toc-icon">üìë</span>
                <span>On this page</span>
            </div>
            <nav class="floating-toc-nav">
                <ul class="floating-toc-list">
                    <!-- Populated by JS -->
                </ul>
            </nav>
        </aside>

        <div class="container">
            <article class="document-article" role="main" id="main-content">
                <!-- Top Navigation -->
                <nav class="document-nav" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">Contents</span>
                        </a>
                        
                        <a href="03-adrenal-pancreas-emergency.html" class="nav-button nav-button--prev" aria-label="Previous section">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Adrenal & Emergency</span>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span class="progress-current">04</span>
                                <span class="progress-separator">/</span>
                                <span class="progress-total">05</span>
                            </div>
                            <div class="progress-bar-container" aria-hidden="true">
                                <div class="progress-bar-fill" style="width: 80%;"></div>
                            </div>
                            <span class="progress-label">Oral Antidiabetics</span>
                        </div>
                        
                        <a href="05-insulin-advanced.html" class="nav-button nav-button--next" aria-label="Next section">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>

                <!-- Breadcrumb -->
                <nav class="breadcrumb" aria-label="Breadcrumb">
                    <ol class="breadcrumb-list">
                        <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                        <li class="breadcrumb-item active" aria-current="page">Oral Antidiabetic Agents</li>
                    </ol>
                </nav>

                <!-- Document Header -->
                <header class="document-header">
                    <div class="header-badge">
                        <span class="badge-icon">üíä</span>
                        <span class="badge-text">Pharmacology</span>
                    </div>
                    <h1 class="document-title">Oral Antidiabetic Agents</h1>
                    <div class="title-meta">
                        <span class="meta-item">
                            <span class="meta-icon">üìÑ</span>
                            <span>Section 4 of 5</span>
                        </span>
                    </div>
                </header>

                <!-- Main Content Area -->
                <div class="content-wrapper">
                    
                    <!-- START: Introduction -->
                    <section id="introduction" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">01</div>
                            <h2 class="section-title">Introduction & Classification</h2>
                        </div>
                        
                        <div class="content-card">
                            <p>Used to stimulate insulin secretion from the pancreas is patients with NIDDM.</p>
                            <p>Four Pharmacologic classes:</p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Insulin secretagogues -sulfonylureas, meglitinides, Dphenylalanine derivatives</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Biguanides</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Thiazolidinediones</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Alpha-glucosidase inhibitors</span>
                                </li>
                            </ol>
                            <p>Other:</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Pramlintide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">exenatide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">sitagliptin</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Introduction -->

                    <!-- START: Insulin Secretagogues -->
                    <section id="insulin-secretagogues" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">02</div>
                            <h2 class="section-title">1. Insulin Secretagogues</h2>
                        </div>

                        <div class="content-card">
                            <h3>Mechanism and effects</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Secretagogues stimulate the release of endogenous insulin by promoting closure of potassium channels in the pancreatic B cell membrane.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Channel closure depolarizes the cell and triggers insulin release.</span>
                                </li>
                            </ul>
                            <aside class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <span class="callout-title">Important</span>
                                </div>
                                <div class="callout-content">
                                    <p>Insulin secretagogues are not effective in patients who lack functional pancreatic B cells.</p>
                                </div>
                            </aside>
                        </div>

                        <!-- Sulfonylureas -->
                        <div class="content-card">
                            <h3 style="color: var(--color-primary);">A. Sulfonylureas</h3>
                            <p>There are 2 groups:</p>
                            <p><strong>1$^{\text {st }}$ generation sulfonylureas; older agents</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Tolbutamide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Chlorpropamide</span>
                                </li>
                            </ul>
                            
                            <p><strong>2$^{\text {nd }}$ generation sulfonylureas</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Glyburide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Glipizide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Glimepiride</span>
                                </li>
                            </ul>
                            <p>Are considerably more potent and used more commonly than the older agents. Have a rapid onset and short duration of action. Administered just before a meal (to control postprandial glucose levels).</p>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Tolbutamide (Orinase)</span>
                                </summary>
                                <div class="collapsible-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">1$^{\text {st }}$ generation</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Well absorbed</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Rapidly metabolized in the liver</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Its duration of effect is relatively short, with an elimination half-life of 4-5 hours</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Best administered in divided doses</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Because of its short half-life, it is the safest sulfonylurea for elderly diabetics</span>
                                        </li>
                                    </ul>
                                    <p><strong>ADRs:</strong> Prolonged hypoglycemia has been reported rarely, mostly in patients receiving certain drugs that inhibit the metabolism of tolbutamide e.g, dicumarol, phenylbutazone, some sulfonamides)</p>
                                </div>
                            </details>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Chlorpropamide (Diabinese)</span>
                                </summary>
                                <div class="collapsible-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Half-life of 32 hours</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Slowly metabolized in the liver to products that retain some biologic activity</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Approximately 20-30% is excreted unchanged in the urine</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Contraindicated in patients with hepatic or renal insufficiency</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Dosages higher than 500 mg daily increase the risk of jaundice</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">The average maintenance dosage is 250 mg daily, given as a single dose in the morning</span>
                                        </li>
                                    </ul>
                                    <p><strong>ADRs:</strong></p>
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Prolonged hypoglycemic reactions are more common in elderly patients, and the drug is contraindicated in this group</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Hyperemic flush after alcohol ingestion in genetically predisposed patients and dilutional hyponatremia</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Hematologic toxicity (transient leukopenia, thrombocytopenia) occurs in less than 1% of patients</span>
                                        </li>
                                    </ul>
                                </div>
                            </details>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Tolazamide (Tolinase)</span>
                                </summary>
                                <div class="collapsible-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Comparable to chlorpropamide in potency but has a shorter duration of action</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">More slowly absorbed than the other sulfonylureas</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Its effect on blood glucose does not appear for several hours</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Its half-life is about 7 hours</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Is metabolized to several compounds that retain hypoglycemic effects</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">If more than $500 \mathrm{mg} / \mathrm{d}$ are required, the dose should be divided and given twice daily</span>
                                        </li>
                                    </ul>
                                </div>
                            </details>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Glyburide (Micronase)</span>
                                </summary>
                                <div class="collapsible-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Metabolized in the liver into products with very low hypoglycemic activity.</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">The usual starting dosage is $2.5 \mathrm{mg} / \mathrm{d}$ or less, and the average maintenance dosage is 5-10 $\mathrm{mg} / \mathrm{d}$ given as a single morning dose</span>
                                        </li>
                                    </ul>
                                    <p><strong>ADRs:</strong></p>
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Potential for causing hypoglycemia</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Flushing has rarely been reported after ethanol ingestion</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Slightly enhances free water clearance</span>
                                        </li>
                                    </ul>
                                    <p><strong>Contraindication:</strong></p>
                                    <ol class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Hepatic impairment</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Patients with renal insufficiency</span>
                                        </li>
                                    </ol>
                                </div>
                            </details>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Glipizide (Glucotrol)</span>
                                </summary>
                                <div class="collapsible-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Half-life ;2-4 hours</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">For maximum effect in reducing postprandial hyperglycemia, this agent should be ingested 30 minutes before breakfast- absorption is delayed when the drug is taken with food</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">The recommended starting dosage is $5 \mathrm{mg} / \mathrm{d}$, with up to $15 \mathrm{mg} / \mathrm{d}$ given as a single dose</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">When higher daily dosages are required, they should be divided and given before meals.</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Maximum recommended total daily dose- 40 mg/d</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">An extended-release preparation - Glucotrol XL provides 24-hour action after a once-daily morning dose</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">At least 90% of glipizide is metabolized in the liver to inactive products,</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">10% is excreted unchanged in the urine</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Contraindication: in patients with significant hepatic or renal impairment- coz of high risk for hypoglycemia</span>
                                        </li>
                                    </ul>
                                </div>
                            </details>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Glimepiride</span>
                                </summary>
                                <div class="collapsible-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Given once-daily as monotherapy or in combination with insulin: A single daily dose of 1 mg</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Achieves blood glucose lowering with the lowest dose of any sulfonylurea compound</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">The recommended maximal daily dose is 8 mg</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Has a long duration of effect with a half-life of 5 hours, allowing once-daily dosing and thereby improving compliance</span>
                                        </li>
                                        <li class="list-item">
                                            <span class="list-marker"></span>
                                            <span class="list-content">Completely metabolized by the liver to inactive products</span>
                                        </li>
                                    </ul>
                                </div>
                            </details>
                        </div>

                        <!-- Meglitinides -->
                        <div class="content-card">
                            <h3 style="color: var(--color-primary);">B. Meglitinides</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">2nd grp of secretor gogues</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Repaglinide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Has a very fast onset of action,</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Peak concentration and peak effect within 1 hour after ingestion,</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Duration of action is 5-8 hours</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Cleared hepatically</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Plasma half-life of 1 hour</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Indicated for use in controlling postprandial glucose excursions coz of it rapid onset of action</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Should be taken just before each meal in doses of 0.25-4 mg (maximum, 16 mg/d);</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hypoglycemia is a risk if the meal is delayed or skipped or contains inadequate carbohydrate</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Should be used cautiously in individuals with renal and hepatic impairment</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Approved as monotherapy or in combination with biguanides</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">There is no sulfur in its structure, so repaglinide may be used in type 2 diabetic individuals with sulfur or sulfonylurea allergy</span>
                                </li>
                            </ul>
                        </div>

                        <!-- D-Phenylalanine Derivative -->
                        <div class="content-card">
                            <h3 style="color: var(--color-primary);">C. D-Phenylalanine Derivative</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Nateglinide: a D-phenylalanine derivative</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">MOA: Stimulates very rapid and transient release of insulin from B cells through closure of the ATP-sensitive $\mathrm{K}^{+}$channel</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">It also partially restores initial insulin release in response to an intravenous glucose tolerance test; a significant advantage of the drug because type 2 diabetes is associated with loss of this initial insulin response</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Has a role in the treatment of individuals with isolated postprandial hyperglycemia,</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Has minimal effect on overnight or fasting glucose levels</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Efficacious when given alone or in combination with nonsecretagogue oral agents (such as metformin)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Dose titration is not required</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Ingested just before meals</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Absorbed rapidly- within 20 minutes after oral administration</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Time to peak concentration is less than 1 hour</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">hepatically metabolized & has a half-life of 1.5 hours</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The overall duration of action is less than 4 hours</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Nateglinide amplifies the insulin secretory response to a glucose load but has a markedly diminished effect in the presence of normal glucose levels;</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Is Therefore safe in individuals with very reduced renal function</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Insulin Secretagogues -->

                    <!-- START: Biguanides -->
                    <section id="biguanides" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">03</div>
                            <h2 class="section-title">2. Biguanides</h2>
                        </div>

                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">$2^{\text {nd }}$ grp; oral hypoglycemics</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Eg. Metformin</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Phenformin cause lactic acidosis and because therefore no longer in use</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Biguanide therapy is not known to cause hypoglycemia</span>
                                </li>
                            </ul>

                            <h4>Mechanisms of Action</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Inhibit hepatic and renal gluconeogenesis</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Stimulation of glucose in peripheral tissues</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Slowing of glucose absorption from the gastrointestinal tract, and</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Reduction of plasma glucagon levels</span>
                                </li>
                            </ul>

                            <h4>Clinical Use</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">In patients with insulin resistance, metformin reduces endogenous insulin production presumably through enhanced insulin sensitivity.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Does not increase weight (unlike insulin, secretagogues, or the thiazolidinediones)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Metformin is increasingly the drug of first choice in overweight patients with type 2 diabetes</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Metformin is also used to restore fertility in anovulatory women with polycystic ovary disease (PCOD) and evidence of insulin resistance</span>
                                </li>
                            </ul>

                            <h4>Toxicities</h4>
                            <aside class="callout callout--note">
                                <div class="callout-content">
                                    <p>NB: Unlike the sulfonylureas, the biguanides do not cause hypoglycemia</p>
                                </div>
                            </aside>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Most common toxicity:GIT distress (nausea, diarrhea),</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Can cause lactic acidosis, especially in patients with renal or liver disease, alcoholism, or conditions that predispose to tissue anoxia and lactic acid production (e.g. chronic cardiopulmonary dysfunction).</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Biguanides -->

                    <!-- START: Thiazolidinediones -->
                    <section id="thiazolidinediones" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">04</div>
                            <h2 class="section-title">3. Thiazolidinediones</h2>
                        </div>

                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">$3^{\text {rd }}$ oral hypoglycemic</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Eg thiazolidinediones, rosiglitazone and pioglitazone</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">They are ligands of peroxisome proliferatoractivated receptor-gamma (PPAR-g), part of the steroid and thyroid superfamily of nuclear receptors]</span>
                                </li>
                            </ul>

                            <h4>MOA</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">They act to decrease insulin resistance: Their primary action is the regulation of genes involved in glucose and lipid metabolism and adipocyte differentiation</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">In the adipose tissue, they promotes glucose uptake and utilization and modulates synthesis of lipid hormones or cytokines and other proteins involved in energy regulation</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Tzds also regulate adipocyte apoptosis and differentiation</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Thiazolidinediones -->

                    <!-- START: Alpha-Glucosidase Inhibitors -->
                    <section id="alpha-glucosidase" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">05</div>
                            <h2 class="section-title">4. Alpha-Glucosidase Inhibitors</h2>
                        </div>

                        <div class="content-card">
                            <p>Eg. Acarbose and miglitol</p>
                            <h4>MOA:</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Only monosaccharides, such as glucose and fructose, can be transported out of the intestinal lumen and into the bloodstream</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Complex starches, oligosaccharides, and disaccharides must be broken down into individual monosaccharides before being absorbed in the duodenum and upper jejunum</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">This digestion is facilitated by enteric enzymes, including <strong>pancreatic Œ±-amylase</strong>, and <strong>Œ±-glucosidases</strong> that are attached to the brush border of the intestinal cells.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Acarbose</strong> and <strong>miglitol</strong> are competitive inhibitors of the intestinal Œ±-glucosidases and reduce the postprandial digestion and absorption of starch and disaccharides.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">They therefore minimize upper intestinal digestion and defer digestion and thus absorption of the ingested starch and disaccharides to the distal small intestine, thereby lowering postmeal glycemic excursions and creating an insulin-sparing effect</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Monotherapy with these drugs is associated with a modest drop ( $0.5-1 \%$ ) in glycohemoglobin levels and a fall in fasting glucose levels</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Taken in doses of 25-100 mg just before ingesting the first portion of each meal; therapy should be initiated with the lowest dose and slowly titrated upward</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Can be used as monotherapy or in combination with sulfonylureas in type 2 diabetes an, in which the glycemic effect is additive</span>
                                </li>
                            </ul>

                            <h4>ADRs</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Flatulence, diarrhea, and abdominal pain- result from the appearance of undigested carbohydrate in the colon that is then fermented into short-chain fatty acids, releasing gas- tend to diminish with ongoing use (because chronic exposure to carbohydrate induces the expression of a-glucosidase in the jejunum and ileum, increasing distal small intestine glucose absorption and minimizing the passage of carbohydrate into the colon)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hypoglycemia may occur with concurrent sulfonylurea treatment</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">should be treated with glucose (dextrose) and not sucrose whose breakdown may be blocked</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Contraindications: Patients with inflammatory bowel disease or any intestinal condition that could be worsened by gas and distention</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Both (miglitol and acarbose) are excreted by the kidneys, and should not be prescribed in individuals with renal impairment</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Acarbose has been associated with reversible hepatic enzyme elevation and should be used with caution in the presence of hepatic disease</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Alpha-Glucosidase Inhibitors -->

                    <!-- START: Other Agents -->
                    <section id="other-agents" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">06</div>
                            <h2 class="section-title">Others hypoglycemic agents</h2>
                        </div>

                        <div class="content-card">
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">PRAMLINTIDE</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">EXENATIDE</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">SITAGLIPTIN</span>
                                </li>
                            </ol>

                            <h4>PRAMLINTIDE</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Given as a subcutaneous injection</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Modulates postprandial glucose levels</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Approved for preprandial use in individuals with type 1 and type 2 diabetes</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">It is administered in addition to insulin in those individuals who are unable to achieve their target postprandial blood sugars</span>
                                </li>
                            </ul>
                            <p><strong>MOA</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Suppresses glucagon release</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Delays gastric emptying, and</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Has central nervous system-mediated anorectic effects</span>
                                </li>
                            </ul>

                            <hr>

                            <h4>EXENATIDE</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">An injectable adjunctive therapy in individuals with type 2 diabetes treated with metformin or sulfonylureas who still have suboptimal glycemic control</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Injected subcutaneously within 60 minutes before a meal</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Therapy is initiated at 5 mcg twice daily, with a maximum dosage of 10 mcg twice daily.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">When exenatide is added to preexisting sulfonylurea therapy, the oral hypoglycemic dosage may need to be decreased to prevent hypoglycemia.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">ADRs: The major side effects are nausea (about $44 \%$ of users) and vomiting and diarrhea.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Nausea decreases with ongoing usage</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Other Agents -->

                    <!-- START: Summary -->
                    <section id="summary" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">07</div>
                            <h2 class="section-title">Summary & Combination Therapy</h2>
                        </div>

                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">There is no indication for combining insulin with insulin secretagogues (sulfonylureas, meglitinides, or D-phenylalanine derivatives) in individuals with type 1 diabetes</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Type 1 diabetics with diets very high in starch may benefit from the addition of a-glucosidase inhibitors</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Bedtime insulin has been suggested as an adjunct to oral antidiabetic therapy in patients with type 2 diabetes patients who have not responded to maximal oral therapy</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Individuals unable to achieve glycemic control with bedtime insulin generally require full insulin replacement and multiple daily injections of insulin</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Insulin secretagogues are redundant when an individual is receiving multiple daily insulin injections</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Multiple oral agents have been required together with insulin in some cases</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Summary -->

                </div>

                <!-- Bottom Navigation -->
                <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="03-adrenal-pancreas-emergency.html" class="nav-button nav-button--prev nav-button--large">
                            <span class="nav-icon">‚Üê</span>
                            <div class="nav-content">
                                <span class="nav-label">Previous</span>
                                <span class="nav-title">Adrenal & Emergency</span>
                            </div>
                        </a>
                        
                        <a href="../index.html" class="nav-button nav-button--toc">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">All Topics</span>
                        </a>
                        
                        <a href="05-insulin-advanced.html" class="nav-button nav-button--next nav-button--large">
                            <div class="nav-content">
                                <span class="nav-label">Next</span>
                                <span class="nav-title">Insulin Advanced</span>
                            </div>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>